

DATABASES

The *FBN2* Gene: New Mutations, Locus-Specific Database (Universal Mutation Database *FBN2*), and Genotype-Phenotype Correlations

Melissa Yana Frédéric,^{1,2} Christine Monino,^{1,2} Christoph Marschall,³ Dalil Hamroun,⁴ Laurence Faivre,^{5–7} Guillaume Jondeau,^{8–11} Hanns-Georg Klein,³ Luitgard Neumann,¹² Elodie Gautier,^{6,13} Christine Binquet,^{6,13} Cheryl Maslen,¹⁴ Maurice Godfrey,¹⁵ Prateek Gupta,¹⁶ Dianna Milewicz,¹⁶ Catherine Boileau,^{8,17–19} Mireille Claustres,^{1,2,4} Christophe Bérout,^{1,2,4} and Gwenaëlle Collod-Bérout^{1,2*}

¹INSERM, U827, Montpellier, F-34000 France; ²Université Montpellier1, Unité Fonctionnelle de Recherche (UFR) de Médecine, Laboratoire de Génétique Moléculaire, Montpellier, F-34000 France; ³Center of Human Genetics and Laboratory Medicine, Martinsried, Germany; ⁴CHU Montpellier, Hôpital Arnaud de Villeneuve, Laboratoire de Génétique Moléculaire, Montpellier, F-34000 France; ⁵CHU Dijon, Hôpital d'Enfants, Centre de Génétique, Dijon, F-21000 France; ⁶Centre d'Investigation Clinique—Épidémiologie Clinique/Essais Cliniques, Dijon, F-21000 France; ⁷Univ de Bourgogne, Dijon, F-21000 France; ⁸AP-HP, Hôpital Bichat, Consultation Marfan, Paris, F-75018 France; ⁹AP-HP, Hôpital Bichat, Service de Cardiologie, Paris, F-75018 France; ¹⁰INSERM, Paris, France; ¹¹Université Paris 7, UFR Médecine, Service de Cardiologie, Paris, F-75018 France; ¹²Charité Campus Virchow-Klinikum, Berlin, Germany; ¹³INSERM, CIE1, Dijon, F-21000 France; ¹⁴Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, Oregon; ¹⁵Center for Human Molecular Genetics, University of Nebraska Medical Center, Omaha, Nebraska; ¹⁶Department of Internal Medicine and Neurosurgery, The University of Texas Medical School, Houston, Texas; ¹⁷INSERM, U781, Paris, F-75015 France; ¹⁸AP-HP, Hôpital Ambroise Paré, Laboratoire Central de Biochimie, d'Hormonologie et de Génétique Moléculaire, Boulogne, F-92100 France; ¹⁹Université Versailles Saint Quentin-en-Yvelines, UFR Paris-Ile-de-France-Ouest (PIFO), Garches, F-92000 France

Communicated by A. Jamie Cuticchia

Congenital contractural arachnodactyly (CCA) is an extremely rare disease, due to mutations in the *FBN2* gene encoding fibrillin-2. Another member of the fibrillin family, the *FBN1* gene, is involved in a broad phenotypic continuum of connective-tissue disorders including Marfan syndrome. Identifying not only what is in common but also what differentiates these two proteins should enable us to better comprehend their respective functions and better understand the multitude of diseases in which these two genes are involved. In 1995 we created a locus-specific database (LSDB) for *FBN1* mutations with the Universal Mutation Database (UMD) tool. To facilitate comparison of identified mutations in these two genes and search for specific functional areas, we created an LSDB for the *FBN2* gene: the UMD-*FBN2* database. This database lists 26 published and six newly identified mutations that mainly comprise missense and splice-site mutations. Although the number of described *FBN2* mutations was low, the frequency of joint dislocation was significantly higher with missense mutations when compared to splice site mutations. The database is freely available at <http://umd.be>. Hum Mutat 0, 1–10, 2008. © 2008 Wiley-Liss, Inc.

KEY WORDS: fibrillin; *FBN2*; Beals-Hecht syndrome; congenital contractural arachnodactyly; CCA; database

INTRODUCTION

Congenital contractural arachnodactyly (CCA; MIM# 121050), or Beals-Hecht syndrome, is an autosomal dominant disease related to Marfan syndrome (MFS; MIM# 154700). These two similar syndromes are heritable connective tissue disorders caused by mutations in two genes belonging to the same family, the fibrillin family: *FBN1* and *FBN2*, encoding fibrillin-1 and fibrillin-2, respectively. CCA was first described by Epstein et al. [1968] and subsequently by Grenier et al. [1969], several years before it was differentiated from MFS by Beals and Hecht [1971]. However, it has been suggested that the first CCA patient was reported, in fact, by Antoine-Bernard Marfan in 1896 [Marfan, 1896] with the description of the little girl Gabrielle who probably presented with

Additional Supporting Information may be found in the online version of this article.

Received 16 October 2007; accepted revised manuscript 19 February 2008.

*Correspondence to: Gwenaëlle Collod-Bérout, PhD, INSERM U827, Institut Universitaire de Recherche Clinique, 641 av du doyen Gaston Giraud, 34093 Montpellier Cedex 5. France.


E-mail: g.collod-berout@inserm.montp.fr

Grant sponsors: Université Montpellier I; INSERM; GIS-Institut des Maladies Rares 2004; Grant sponsor: Association Française contre les Myopathies (AFM); Grant number: AFM-R07017FF; Grant sponsor: Agence Nationale pour la Recherche (ANR); Grant number: ANR-05PCOD-14-02.

Melissa Frederic and Christine Monino contributed equally to this work.

DOI 10.1002/humu.20794

Published online in Wiley InterScience (www.interscience.wiley.com).



CCA rather than MFS. Clinical diagnosis is difficult because there are numerous common characteristics shared between MFS and CCA, such as a so-called marfanoid appearance constituted by tall, slender, asthenic appearance and skeletal features such as arachnodactyly, dolichostenomelia, pectus deformities, and kyphoscoliosis. In contrast with MFS, most individuals with CCA have “crumpled” ears, flexion contractures, and muscular hypoplasia. CCA is a disease with a relatively good prognosis because, despite the fact that aortic dilatation has been documented in a few patients (3/47; see Supplementary Table S1; available online at <http://www.interscience.wiley.com/jpages/1059-7794/suppmat>), the progression of dilatation to aortic dissection has not been documented. Lethal forms of CCA are rare and are related to additional abnormalities on top of skeletal and ear features; either in the gastrointestinal system (duodenal or esophageal atresia, intestinal malrotation) or in the cardiovascular system (atrial or ventricular septal defects, interrupted aortic arch, single umbilical artery), consequences of alteration in development.

CCA is an autosomal dominant disorder. Its incidence is unknown, as well as the percentage of cases caused by de novo mutations. As with MFS, CCA does not have gender or ethnic predilection. It appears to be fully penetrant. Finally, germline mosaicism has been observed [Putnam et al., 1997; Wang et al., 1996].

To date, little is known about *FBN2* mutations and their clinical spectrum. More data are available on *FBN1* mutations that are implicated in MFS and numerous related pathologies such as severe neonatal Marfan syndrome [Kainulainen et al., 1994], autosomal dominantly inherited ectopia lentis (MIM# 129600) [Ades et al., 2004; Kainulainen et al., 1994; Lonnqvist et al., 1994], isolated skeletal features (or Marfanoid skeletal syndrome) [Milewicz et al., 1995], atypical MFS without cardiac involvement, involvement of the mitral valve, aorta, skeleton, and skin (the “MASS phenotype”), familial or isolated forms of aortic aneurysms [Milewicz et al., 1996], and autosomal dominant Weill-Marchesani syndrome (MIM# 227600) [Favre et al., 2003]. The Universal Mutation Database (UMD)-*FBN1* locus-specific database (LSDB) today contains more than 1,700 mutations [Collod-Beroud et al., 2003; Favre et al., 2007].

The aim of our work was to create a new UMD database, to better analyze *FBN2* mutations and to compare them with *FBN1* mutations. Although the two genes display strong homology and similar modular organization, it is still unknown exactly what differentiates them functionally. The different roles of *FBN1* and *FBN2* could be explained by different promoters allowing spatiotemporally different expression and/or by different protein-protein interactions. Identifying mutations in specific regions of the two genes could allow identification of the functional regions of these two proteins. In order to accumulate and easily compare molecular and clinical data, we created a new LSDB, the UMD-*FBN2* database.

FIGURE 1. Comparison of the distribution of *FBN1* and *FBN2* mutations. A: Distribution of *FBN1* and *FBN2* mutations per exon. The number for each type of mutation (missense, deletions, insertions/duplications, and nonsense) is represented for each exon. Splice mutations are not part of this graph. Distribution of mutations identified in the *FBN1* gene (second graph) or associated with neonatal MFS (first graph) are compared with mutations identified in the *FBN2* gene and implicated in CCA (third graph). B: Schematic representation of the deduced primary structure of fibrillin-2. Part of the fibrillin-2 protein corresponding to exons 24 to 33, where mutations implicated in CCA are clustered, is boxed.

THE *FBN2* GENE IS HOMOLOGOUS TO *FBN1*

The *FBN2* gene was discovered while cloning the gene implicated in Marfan syndrome, the *FBN1* gene located in 15q15–21.3. *FBN2* maps in 5q23–31 [Lee et al., 1991]. The demonstration that mutations in the *FBN2* gene were involved in CCA was made by genetic linkage analysis [Lee et al., 1991; Tsipouras et al., 1992] and the first implication of a *FBN2* mutation in CCA was reported by Putnam et al. [1995].

FBN2 is a 279.57-kb gene (contig NT_034772) that encodes a 10,166-bp transcript and a 2,912-amino acid protein. The *FBN1* and *FBN2* genes are highly homologous at the nucleotide level; on comparison of 58% of the sequence, we obtained 84% homology between *FBN1* and *FBN2*. The fibrillin family contains another member, *FBN3*, identified from a human fetal brain library [Nagase et al., 2001]. *FBN3* is located in 19p13.3–19p13.2 and is composed of 65 exons. Its structure substantially resembles that of *FBN1* and *FBN2*: amino acid identity is high, including conservation of all cysteine residues; and domain organization is consistent throughout each of the proteins [Corson et al., 1993].

The multidomain structure of the genes belonging to the fibrillin family contains five different modules (see representation of *FBN2* secondary structure in Fig. 1B). The most common is the epidermal growth factor (EGF)-like module (by homology to epidermal growth factor) with 47 repeats. This particularly conserved sequence contains six cysteines involved in three disulfide bonds [Rao et al., 1995], which are formed between cysteines 1-3, 2-4, and 5-6 [Downing, et al., 1996]. A total of 43 of these contain a conserved consensus calcium-binding sequence: D/N-X-D/N-E/Q-X_n-D/N*-X_m-Y/F (n and m are variable, * indicates possible β hydroxylation) [Handford et al., 1991; Rees et al., 1988] and have been demonstrated to bind calcium [Corson et al., 1993; Dietz and Pyeritz, 1995; Glanville et al., 1994]. Another motif containing eight cysteines is repeated seven times [Yuan et al., 1997] and is named transforming growth factor binding protein (TGFβP)-like module because of its homology with TGFβ binding protein (also named 8-cys modules) [Yuan et al., 1997]. According to SwissProt, we annotated “signal peptide” from amino acid 1 to 28. By analogy with the well-described *FBN1* structure, we listed other domains not listed in SwissProt: “N-terminal domain” from amino acid 29 through 82 and “C-terminal domain” from amino acid 2,732 through the end of the protein. We annotate also a 4-cysteine motif (4-cys motif), also reported in latent TGF-β binding proteins (LTBPs), from amino acid 83 to 110 [Bashir et al., 1996; Isogai et al., 2003; Olofsson et al., 1995] and a domain presenting with homology to fibulins C-terminal domain III (FibuCTDIII-like motif) from amino acid 2,758 to 2,912 [Giltay et al., 1999]. The protein sequence encoded by *FBN2* also contains two arginine-glycine-aspartate (RGD) sequences, only one of which is present in *FBN1*. These sequences allow interaction with integrin receptors, which are present at the surface of cells, permitting cells to anchor to the extracellular matrix. One of these sequences is situated in exon 24 corresponding to codons 1,061 to 1,063, the other one, specific to *FBN2* sequence, is in exon 37 corresponding to codons 1,586 to 1,588 [Ritty et al., 2003]. Finally, we annotated 12 *FBN2* N-glycosylation sites conserved in *FBN1* that contains a total of 15 amino acid residues: 492; 1,112; 1,414; 1,529; 1,625; 1,714; 1,745; 1,756; 1,945; 2,120; 2,225; and 2,808 [Ramirez and Pereira, 1999], and very conserved amino acids of unknown function in calcium binding (cb)EGF-like, TGFβP-like, EGF-like modules, as well as in 4-cys motif (Cterm) and in FibuCTDIII-like motif

(Nterm). However, contrary to *FBN1* and according to the *FBN2* sequence, we have not identified furine/pase (consensus site R-X-K/R-R) or matrix metalloproteinase sites. To our knowledge, these sites have not been reported in the *FBN2* gene.

EXPRESSION OF *FBN2* AND *FBN1* GENES AND PROTEIN FUNCTION

The two ~320-kD proteins encoded by *FBN1* and *FBN2*, fibrillin-1 and fibrillin-2, respectively, are also highly homologous in terms of amino acid sequences. These large cysteine-rich glycoproteins are major components of microfibrils from extracellular matrix, which can be associated with elastin fibers. In organ culture experiments, both fibrillins are similarly expressed in most tissues, except for kidney, liver, rib anlage, and notochord [Quondamatteo et al., 2002]. However, temporal expression of the two proteins is quite different during embryogenesis. Fibrillin-2 is expressed earlier in development [Mariencheck et al., 1995], except in the cardiovascular system, and appears to have a potential role in elastogenesis, while fibrillin-1 is expressed later and has a fundamental structural role. Moreover, fibrillin-2 is expressed mostly during embryogenesis by very different types of tissues [Zhang et al., 1994, 1995]. By studying a rat model, it has been suggested that fibrillin-2 could play a role in lung development [Yang et al., 1999]. Fibrillin-1 and fibrillin-2 could perform equivalent architectural functions in some tissues while fibrillin-2 may have a distinct function in peripheral nerves [Charbonneau et al., 2003].

The two proteins can be divided into five regions called A, B, C, D, and E. The most different domains are the A domains, with 19% homology between the two fibrillins; the C domain, which is proline-rich in fibrillin-1 and glycine-rich in fibrillin-2; and the E domain, with 50% homology. The two domains B and D share more homologies, with 87% and 81% homology, respectively. This can be explained by the high representation of conserved modules presenting homology to EGF; called the EGF-like module [Corson et al., 1993; Pereira et al., 1993].

THE UMD-*FBN2* DATABASE

Codons are numbered with respect to the *FBN2* gene cDNA sequence (+1 = A of ATG). Two reference sequences have been used in previous mutation reports. These two references differ in their nucleotide sequence and by the presence of an additional amino acid (A₁₉₂Q₁₉₃P₁₉₄ in HGMD and SwissProt; or G₁₉₂P₁₉₃N₁₉₄R₁₉₅ in GenBank NM_001999). As sequencing of more than 150 individuals only displayed “G₁₉₂P₁₉₃N₁₉₄R₁₉₅” (C. Maslen, and C. Marschall, personal communication), mutation names were renumbered with respect to the *FBN2* gene cDNA sequence obtained from the GenBank database (GenBank database accession number NM_001999, complete coding sequence of human fibrillin-2). Amino acid numbers can then be different from those published (add +1 to the published amino acid [AA] number and +3 to the published nucleotide number for residues located downstream of AA 195).

Intron-exon boundaries, as well as intronic sequences, were defined by matching the cDNA sequence to the corresponding genome sequence (NT_0347772) and module organization from SwissProt (accession number P35556 with corrections for residues located downstream of AA 195). The database follows the guidelines on mutation databases of the Hugo Mutation Database Initiative including the latest nomenclature (www.hgvs.org).

We have used UMD software to create a computerized database that currently contains information about the published mutations of the *FBN2* gene, mutations only reported in meeting proceedings or contributed by the coauthors of this work. The mutation records can list point mutations, large and small deletions, insertions, and mutations affecting splicing (intronic mutation) in the *FBN2* gene. It cannot accommodate complex mutations. In addition, two mutations affecting the same allele will be entered as two different records linked by the same sample ID. For each mutation, information is provided at different levels: genetic (exon and codon number, wild-type and mutant codon, mutational event, mutation name), protein (wild-type and mutant amino acid, affected domain, mutation name), and clinical (skeletal, cardiovascular, gastrointestinal symptoms, when data are available).

We have annotated the *FBN2* sequence with all indirect arguments to define whether potential missense mutations are really causative. These arguments list cysteines implicated in disulfide bonds in EGF-like, cbEGF-like, and TGFβ-like modules according to SwissProt [Downing et al., 1996; Rao et al., 1995], N-glycosylated amino acids [Ramirez and Pereira, 1999], amino acids implicated in RGD sequences [Ritty et al., 2003], and highly conserved amino acids of unknown function in cbEGF-like, TGFβ-like, and EGF-like modules, as well as in 4-cys motif (Cterm) and in FibuCTDIII-like motif (Nterm).

Study of the database can be done with different routines described on our internet website at www.umd.be. It is possible to analyze mutation distribution by exon, mutation distribution by mutation type, and mechanism for deletion/insertion [Beroud et al., 2000, 2005]. With the annotation highly conserved domain (“HCD”), it is possible to know if an amino acid has a known function in the protein.

The software has already been used successfully for other genes implicated in genetic diseases, such as *FBN1* [Collod et al., 1996; Collod-Beroud et al., 1997, 1998, 2003], *LDLR* [Varret et al., 1997, 1998; Villeger et al., 2002], *TGFβR2* (submitted), *TGFβR1* (in construction), *ALS2*, *ATP7B*, *CAPN3*, *CDH23*, *CFTR*, *DMD*, *DPYD*, *DYSF*, *EIF2*, *EMD*, *EIF2B*, *GJB2*, *GFAP*, *LMNA*, *MYO7A*, *PCDH15*, *PLP1*, *TGFβR1*, *USH1C*, *USH2A*, *USH3A*, *SANS*, *SGCA*, *SGCG*, *FKRP*, and *ZMPSTE24* (unpublished); and for different types of genes implicated in cancer, such as *TP53* [Bérout and Soussi, 1997, 1998, 2003; Bérout et al., 1996; Soussi et al., 2000], *APC* [Bérout and Soussi, 1996, 1997; Laurent-Puig et al., 1998], *MEN1* [Wautot et al., 2002], *VHL* [Bérout et al., 1998; Gallou et al., 1999], *WT1* [Jeanpierre et al., 1998], *BRCA1*, *BRCA2*, *MEN1*, *MLH1*, *MSH2*, *MSH6*, *MYH*, *PMS2*, and *SUR1* (unpublished). More information concerning the UMD software is available at www.umd.be [Beroud et al., 2000, 2005].

The current database and subsequent updated versions are available online at www.umd.be. Notifications of omissions and errors in the current version as well as specific phenotypic data would be gratefully received by the corresponding author. The software will be expanded as the database grows and according to the requirements of its users, and new functions may be implemented.

MUTATION ANALYSIS

Today, the database contains 32 entries indexed in the UMD-*FBN2* locus specific database (Tables 1 and 2). One mutation is only reported in a meeting proceeding (p.E390K) [Wang et al., 1995b]. A total of 25 are published mutations [Babcock et al., 1998; Belleh et al., 2000; Gupta et al., 2002, 2004; Maslen et al., 1997; Nishimura et al., 2007; Park et al., 1998; Putnam et al., 1995, 1997; Wang et al., 1995b, 1996] and six mutations are contributed by the coauthors of this work

TABLE 1. Missense, nonsense and insertion/duplication/FBN2 mutations*

Nomenclature	Exon	Codon	WT codon	Mutant codon	Event	Type	WTAA	Mutant AA	Structure	HCD	Ref#
Missenses											
c.1168G>A	9	390	TGT	AAG	G->A	Ts	Cys	Lys	TGFBP#01	C in disulfide bonds 390–417	Wang et al. [1995a, b]
c.3170G>A	24	1057	GGC	GAC	G->A	Ts	Gly	Asp	TGFBP#03	Conserved AA in TGFBP	Park et al. [1998]
c.3278T>C	25	1093	ATC	ACC	T->C	Ts	Ile	Thr	cb EGF-like#11	Ca2+-binding	Park et al. [1998]
c.3425G>A	26	1142	TGC	TAC	G->A	Ts	Cys	Tyr	cb EGF-like#12	C in disulfide bonds 1142–1156	This report
c.3425G>T	26	1142	TGC	TTC	G->T	Tv	Cys	Phe	cb EGF-like#12	C in disulfide bonds 1142–1156	Belleh et al. [2000]
c.3535G>T	27	1179	GGC	TGC	G->T	Tv	Gly	Cys	cb EGF-like#13	Ca2+-binding	Gupta et al. [2002]
c.3593G>A	27	1198	TGT	TAT	G->A	Ts	Cys	Tyr	cb EGF-like#13	C in disulfide bonds 1185–1198	Gupta et al. [2002]
c.3718T>C	28	1240	TGT	CGT	T->C	Ts	Cys	Arg	cb EGF-like#14	C in disulfide bonds 1227–1240	Gupta 2002
c.3758G>A	29	1253	TGT	TAT	G->A	Ts	Cys	Trp	cb EGF-like#15	C in disulfide bonds 1253–1266	Putnam et al. [1995]
c.3759T>G	29	1253	TGT	TGG	T->G	Tv	Cys	Trp	cb EGF-like#15	C in disulfide bonds 1253–1266	Belleh et al. [2000]
c.3771C>G	29	1257	TGC	TGG	C->G	Tv	Cys	Trp	cb EGF-like#15	C in disulfide bonds 1246–1257	Gupta et al. [2002]
c.3802T>C	29	1268	TGC	CGC	T->C	Ts	Cys	Arg	cb EGF-like#19	C in disulfide bonds 1268–1281	Gupta et al. [2002]
c.4274G>T	33	1425	ATG	TTT	G->T	Tv	Cys	Phe	cb EGF-like#19	C in disulfide bonds 1412–1425	This report
c.4301G>C	33	1434	TGT	TCT	G->C	Tv	Cys	Ser	cb EGF-like#19	C in disulfide bonds 1420–1434	Putnam et al. [1995]
C.976c>t	8	326	CCT	TCT	C->T	Ts	Pro	Ser	cb EGF-like#02		This report
Insertion/duplication											
c.3269.3271dup	25	1091	AAT	Ins3b	In = frame ins	Fr.	Asn	InF	Cb EGF-like#11	Ca2+-binding	This report
Nonsense											
c.4296C>A	33	1432	TAC	TAA	C->A	Tv	Tyr	Stop	Cb EGF-like#19	Ca2+-binding	Gupta 2002

*Each line represents a single FBN2 mutation report. Codons are numbered with respect to the FBN2 gene cDNA sequence (+1 = A of ATG). If the mutation predicts a premature protein-termination, the novel stop codon position is given, e.g., "Stop at 130." Module group is numbered separately and according to the position of the module with respect to the amino-terminal end of the protein.

TABLE 2. Splice FBN2 mutations*

Mutation	Splice site type	Wild type sequence	WT CV	Mutant sequences	Mutant CV	Variation	Reference
Acceptor splice sites							
c.IVS33-2A>T (c.4346-2A>T)	Acceptor	gctttttgcacagA	94.61	gctttttgcacagA	78.69	-16.83	Wang et al. [1996]
c.IVS28-3C>G (3725-3C>G)	Acceptor	tgctgtttcacagA	93.13	tgctgtttcacagA	80.71	-13.34	This report
c.IVS30-5T>G (c.3974-5T>G)	Acceptor	aataaatttctagA	68.16	aataaatttctagA	61.68	-9.51	Nishimura et al. [2007]
Donor splice sites							
Donor splice sites							
c.IVS31+1G>C (c.4099+1G>C)	Donor	AGgttaggt	68.54	AGcttaggt	70.36	-20.53	Park et al. [1998]
c.IVS26+2T>C (c.3472+2T>C)	Donor	GGgtaagc	86.73	GGgcaagc	68.54	-20.96	Gupta et al. [2002]
c.IVS26+2T>G (c.3472+2T>G) ^a	Donor	GGgtaagc	86.73	GGggaagc	68.54	-20.96	Gupta et al. [2002]
c.IVS32+5G>A (c.4222+5G>A)	Donor	TGgtgagt	89.64	TGgtgagt	75.10	-16.23	Gupta 2002
c.IVS32+2T>C (c.4222+2T>C)	Donor	TGgtgagt	89.64	TGgcgagt	71.45	-20.29	This report
c.IVS31+1G>A (c.2099+1G>A)	Donor	AGgttaggt	88.55	AGataggt	70.36	-20.53	Nishimura et al. [2007]
c.IVS35+1G>T (c.4594.1G>T)	Donor	AGgtatgg	83.64	AGhtatgg	65.45	-21.74	Nishimura et al. [2007]
c.3343G>C (last base of exon 25)	Donor	GGggtaaga	86.36	GCggtaga	72.54	-16.00	Babcock et al. [1998]
Mutations not localised in canonical sequences							
c.IVS28-15A>G (c.3725-15A>G)	Cryptic acceptor?	caatgtgttgcgaat	58.58	caatgtgttgcag	74.50	21.37	Putnam et al. [1997]
c.IVS30-26G>T (c.3974-26G>T)	No branch point modification, no creation of splice site consensus						Maslen et al. [1997]
c.IVS30-24A>C (c.3974-24A>C)	No branch point modification, no creation of splice site consensus						Nishimura et al. [2007]

* Consensus values for each potential donor or acceptor splice site are calculated for Wild Type (WT) and mutant sequence according to Senapathy et al. [1990]; and Shapiro and Senapathy [1987]) (100 = strong splice site; 0 = not a splice site).
^a Identified twice.

(Christoph Marschall, Hans George Klein, and Luitgard Neumann).

Complex Mutation

One is a complex genomic rearrangement consisting in skipping of exon 24 and duplication of exon 23 [Gupta et al., 2002] and cannot be indexed in the database.

Nonsense and Missense Mutations

Only one reported mutation is a nonsense mutation: c.4296C>A [Gupta et al., 2002]. A total of 15 are missense mutations. A total of 11 are mutations which modify a cysteine residue implicated in a disulfide bond: c.1198G>A [Wang et al., 1995b]; c.3758G>A and c.4301G>C [Putnam et al., 1995]; c.3425G>T and c.3759T>G [Belleh et al., 2000]; c.3593G>A, c.3718T>C, c.3771C>G, and c.3802T>C [Gupta et al., 2002]; and c.3425G>A and c.4274G>T (this report). There are three mutations modifying an amino acid residue potentially implicated in Ca²⁺ binding, according to Dietz and Pyeritz [1995]: c.3340G>C [Babcock et al., 1998]; c.3278T>C [Park et al., 1998]; and c.3535G>T [Gupta et al., 2002]. One is a mutation that modifies an amino acid residue conserved in TGF β -like domains: c.3170G>A [Park et al., 1998]. All 15 missense mutations (including the c.976C>T mutation not located in an HCD) are predicted to be pathogenic according to conservation and biochemical data with the UMD-Predictor tool (unpublished results).

Insertion/Duplication

Only one reported mutation is an insertion, corresponding to a small duplication of an existing three-base sequence.

Splice-Site Mutations

A total of 14 are splice mutations. Three mutations modify an acceptor splice-site: c.IVS33–2A>T [Wang et al., 1996], c.IVS28–3C>G (this report), and c.IVS30–5T>G [Nishimura et al., 2007]; and eight modify a donor splice-site: c.IVS31+1G>C [Park et al., 1998], c.IVS26+2T>C and c.IVS26+2T>G [Gupta et al., 2002], c.IVS32+5G>A [Gupta et al., 2004], c.IVS32+2T>C (this report), c.IVS31+1G>A and c.IVS35+1G>T [Nishimura et al., 2007], and c.3343G>C (last base of exon 25, in donor splice-site consensus) [Babcock, et al., 1998]. The software can compute the variation of the consensus value (CV) of the mutant “splice-site” vs. the wild-type. Wild type, mutated CVs as well as the variation between these values are indicated in Table 2. If variation is >10%, it is highly probable that the mutated site is preferred to the wild-type. As observed in Table 2, significant variations are found for 10 out of the 11 mutations. More arguments are then needed for the c.IVS30–5T>G mutation (variation of –9,51) [Nishimura et al., 2007]. Alternative splicing has been demonstrated in only five cases at the RNA level (Table 2). Three mutations are not localized in the canonical donor or acceptor splice-site consensus sequences. Two mutations localized in –24 and –26 of intron 30 are in the vicinity of the branchpoint, c.IVS30–26G>T [Maslen et al., 1997] and c.IVS30–24A>C [Nishimura et al., 2007], but do not involve one of the seven nucleotides of the most probable branchpoint consensus sequence (–35 to –29, agcacAt) (see Supplementary Fig. S1). One of these two mutations was confirmed to cause missplicing at the mRNA level [Maslen et al., 1997] thus suggesting the presence of a regulatory sequence in this intronic region. The natural acceptor splice site in intron 30

is weak (68.16) and the disturbance of the surrounding sequence could play an important role in splicing. Further experimental analyses are needed to demonstrate this hypothesis and identify this key sequence regulator. The last mutation not localized in a canonical sequence is c.IVS28–15A>G [Putnam et al., 1997]. This mutation in intron 28 does not involve one of the seven nucleotides of the most probable branchpoint consensus sequence (–34 and –28, acctgAc) (see Supplementary Fig. S4). Furthermore, the natural acceptor splice-site in this intron is strong (89.40). This mutation creates a potential alternative acceptor splice-site (caatgtggtgcag, 74.50). Nevertheless, abnormal splicing corresponding to the skipping of exon 29 has been reported. The mechanism of this skipping is thus unclear.

In conclusion, *FBN2* mutations leading to a premature termination codon are significantly underrepresented (only one nonsense mutation is reported) contrasting with an overrepresentation of in-frame mutations (splice-site mutations are likely all in-frame and the unique duplication results in in-frame insertion). This particular distribution of mutation types is similar in the homologous *FBN1* region (exons 24–32; c.f. paragraph 6). Nevertheless, contrary to *FBN1*, where mutations in this region are mainly missense (56.9% for 12.5% of splice-site mutations), the mutations currently reported in the *FBN2* gene are evenly distributed between missense (50%) and splice-site mutations (46.9%).

STRUCTURE/FUNCTION CORRELATIONS

All known mutations in the *FBN2* gene except two, c.976C>T (this report) and c.1168G>A [Wang et al., 1995a], are clustered in a limited region between exons 24 through 35 (Fig. 1A; graph 3). Curiously, the homologous region in the *FBN1* gene (exons 24–32) clusters almost all mutations implicated in neonatal forms of MFS that correspond to the most severe end of the MFS clinical spectrum [Park et al., 1998] (Fig. 1A; graph 2). Clinical features found in neonatal MFS and CCA can be overlapping as congenital contractures, dolichostenomelia, arachnodactyly, and abnormal ears are found in both cases. Other *FBN1* mutations, implicated in a large spectrum of clinical phenotypes, are spread throughout the gene (Fig. 1A; graph 1). Furthermore, *FBN1* mutations in exons 24 to 32 not implicated in neonatal cases were associated with a more severe phenotype, including younger age at diagnosis, higher probability of ectopia lentis, ascending aortic dilatation, aortic surgery, mitral valve abnormalities, scoliosis, and shorter survival. Therefore, more than a “neonatal region,” it should be considered a “severe region.” The presence of a mutation in this limited *FBN1* region appears to be the best indicator of early onset aortic risk [Faivre et al., 2007]. Only four patients with a known *FBN2* mutation among 47 had aortic root dilation at an early age and none of these individuals are known to have progressed to aortic dissection (Supplementary Table S1). This region seems then to have a different function in fibrillin-2. Nevertheless, even if the presence of a cardiac implication is rare and the prognosis for CCA patients with these abnormalities is not known, cardiac evaluation including echocardiogram must be set up for CCA patients. The most severe end of the CCA clinical spectrum corresponds to a severe/lethal form. Molecular studies of only one individual (IVS33–2A>T [Wang et al., 1996]) among the six cases reported with severe/lethal CCA [Currarino and Friedman, 1986; Godfrey et al., 1995; Lipson et al., 1974; Macnab et al., 1991; Wang et al., 1996] have been performed and the identified mutation is localized in this specific region. It would be very interesting to search for the molecular abnormalities in the other reported cases

and look for their localization in or out of this limited region of the *FBN2* gene.

This middle-*FBN1* region is the beginning of the longest stretch of EGF-like motifs. Immunohistochemical studies of neonatal patients' cell cultures showed important decrease of immunoreactive material when stained with anti-fibrillin-1 antibodies and an abnormal microfibril morphology: fibrils were short, fragmented, and frayed [Raghunath et al., 1993; Superti-Furga et al., 1992]. Rotary shadowing electron microscopy analyses of these cell cultures had no identifiable 10-nm-diameter microfibrils at all [Lonnqvist et al., 1996]. Alteration of this region of the protein then, undoubtedly has a significant and specific effect on fibrillin-1-containing microfibril formation and their stability in the extracellular matrix. Clarifying the specific functional significance of this region in *FBN1* during early development may help in understanding the specific function of the corresponding *FBN2* sequence.

Finally, the clustering of CCA mutations in this *FBN2* region raises the question of the phenotypes associated with mutations localized outside of this region. It is not known today if these *FBN2* mutations are either silent, result in different phenotypes (part of the spectrum of phenotypes associated with a *FBN1* mutation or with no relationship), or are lethal. If the clinical spectrum associated with *FBN2* mutations is comparable with those linked to *FBN1* mutations, mutations localized in this particular region should correspond to the most severe end of the spectrum and mutations that occur outside this region would be associated with milder phenotypes.

GENOTYPE-PHENOTYPE CORRELATIONS

Methodology

To study the effect of mutation type, we compared patients with a missense mutation to patients with a splice-site mutation for each clinical feature: abnormal ears, micrognathia, high arched palate, arachnodactyly, joint contractures, joint dislocation, scoliosis, pectus deformity, pes deformity, dolichostenomelia, orthopedic treatment, and aortic root dilatation and refraction. As the age at diagnosis of each clinical feature was not collected, age at last follow-up was the only information available. To indirectly take into account length of patient of follow-up in this situation, we adjusted all comparisons of CCA manifestation frequencies for the ages at last follow-up, and categorized them into 10-year age groups. These adjusted comparisons were performed using the Mantel-Haenszel (MH) test [Mantel and Haenszel, 1959]. As this test is adopted only if the relationship between the mutation type and the clinical manifestation is similar in the different strata of age at last follow-up, we checked the homogeneity between strata using the Breslow-Day chi-squared test of homogeneity [Breslow and Day, 1987]. If an interaction was observed, results were presented for each category of age at last follow-up. Stata software version 8 (Stata Corp., College Station, TX) was used for all statistical analyses. Only P values <0.005 were considered as significant since multiple tests were performed.

Only mutations with complete clinical descriptions have been taken into account in these analyses (mutations c.4296C>A and c.3269_3271dup excluded). For some mutations, clinical descriptions available for other affected relatives carrying the same *FBN2* mutation were included (IVS26+2T>G, IVS28–15A>G, IVS30–26G>T, IVS32+5G>A, IVS33–2A>T, IVS30–24A>C, c.3170G>A, c.3278T>C, and c.3343G>C) (see Supplementary Fig. S1).

Results

A total of 29 individuals with a splice-site mutation and 19 with a missense mutation were included in these analyses (a total of 23 distinct mutations are taken into account). The only significant result was the frequency of joint dislocation that was significantly higher with missense mutations when compared to splice-site mutations (MH test, $P = 0.0028$).

POLYMORPHISMS

To assist in diagnosis, we also list published or contributed *FBN2* polymorphisms (Supplementary Tables S2 and S3). The aim is to make available a complete set of *FBN2* gene variations (mutations + polymorphisms) to the community, which may be used to quickly identify a causative mutation, thus saving time and money on testing for a polymorphism in a control population. These polymorphisms are numbered according to NM_001999 with G₁₉₂P₁₉₃N₁₉₄R₁₉₅. Coding *FBN2* gene variations are represented in Supplementary Table S2 and noncoding in Supplementary Table S3.

FUTURE PROSPECTS

The clustering of CCA mutations in the limited region between *FBN2* exons 24 through 35 raises the question of the existence or not of phenotypes associated with *FBN2* mutations localized inside and outside of this region. The mutational events in previously reported severe/lethal CCA cases [Currarino and Friedman, 1986; Godfrey et al., 1995; Lipson et al., 1974; Macnab et al., 1991; Wang et al., 1996], as well as in isolated associated CCA signs, such as arthrogyrosis, kyphoscoliosis, and osteopenia, must now be investigated to define just how broad the clinical spectrum associated with *FBN2* mutations is. For example, familial forms of severe scoliosis could be investigated for the presence of *FBN2* gene mutations.

ACKNOWLEDGMENTS

This work was supported by grants from AFM (Association Française contre les Myopathies) (AFM-R07017FF) (to C.Bé. and D.H), Université Montpellier 1, INSERM, GIS-Institut des Maladies Rares 2004 (to C.Boi. and G.J.), and Agence Nationale pour la Recherche (ANR) (ANR-05PCOD-14-02 to C.Boi. and G.J.). M.Y.F. is supported by a grant from AFM.

REFERENCES

- Ades LC, Holman KJ, Brett MS, Edwards MJ, Bennetts B. 2004. Ectopia lentis phenotypes and the *FBN1* gene. *Am J Med Genet A* 126:284–289.
- Babcock D, Gasner C, Francke U, Maslen C. 1998. A single mutation that results in an Asp to His substitution and partial exon skipping in a family with congenital contractural arachnodactyly. *Hum Genet* 103:22–28.
- Bashir MM, Han MD, Abrams WR, Tucker T, Ma RI, Gibson M, Ritty T, Mecham R, Rosenbloom J. 1996. Analysis of the human gene encoding latent transforming growth factor-beta-binding protein-2. *Int J Biochem Cell Biol* 28:531–542.
- Beals RK, Hecht F. 1971. Congenital contractural arachnodactyly. A heritable disorder of connective tissue. *J Bone Joint Surg* 53A:987–993.
- Belleh S, Zhou G, Wang M, Der Kaloustian VM, Pagon RA, Godfrey M. 2000. Two novel fibrillin-2 mutations in congenital contractural arachnodactyly. *Am J Med Genet* 92:7–12.
- Beroud C, Collod-Beroud G, Boileau C, Soussi T, Junien C. 2000. UMD (Universal mutation database): a generic software to build and analyze locus-specific databases. *Hum Mutat* 15:86–94.

- Beroud C, Hamroun D, Collod-Beroud G, Boileau C, Soussi T, Claustres M. 2005. UMD (Universal Mutation Database): 2005 update. *Hum Mutat* 26:184–191.
- Béroud C, Soussi T. 1996. APC gene: database of germline and somatic mutations in human tumors and cell lines. *Nucleic Acids Res* 24:121–124.
- Béroud C, Verdier F, Soussi T. 1996. p53 gene mutation: software and database. *Nucleic Acids Res* 24:147–150.
- Béroud C, Soussi T. 1997. p53 and APC gene mutations: software and databases. *Nucleic Acids Res* 25:138.
- Béroud C, Soussi T. 1998. p53 gene mutation: software and data-base. *Nucleic Acids Res* 26:200–204.
- Béroud C, Joly D, Gallou C, Staroz F, Orfanelli M, Junien C. 1998. Software and database for the analysis of mutations in the VHL gene. *Nucleic Acids Res* 26:256–258.
- Béroud C, Soussi T. 2003. The UMD-p53 database: new mutations and analysis tools. *Hum Mutat* 21:176–181.
- Breslow NE, Day NE. 1987. Statistical methods in cancer research. Volume II: the design and analysis of cohort studies. *IARC Sci Publ* 82:1–406.
- Charbonneau NL, Dzamba BJ, Ono RN, Keene DR, Corson GM, Reinhardt DP, Sakai LY. 2003. Fibrillins can co-assemble in fibrils, but fibrillin fibril composition displays cell-specific differences. *J Biol Chem* 278:2740–2749.
- Collod G, Beroud C, Soussi T, Junien C, Boileau C. 1996. Software and database for the analysis of mutations in the human FBN1 gene. *Nucleic Acids Res* 24:137–140.
- Collod-Beroud G, Beroud C, Ades L, Black C, Boxer M, Brock DJ, Godfrey M, Hayward C, Karttunen L, Milewicz D, Peltonen L, Richards RI, Wang M, Junien C, Boileau C. 1997. Marfan Database (second edition): software and database for the analysis of mutations in the human FBN1 gene. *Nucleic Acids Res* 25:147–150.
- Collod-Beroud G, Beroud C, Ades L, Black C, Boxer M, Brock DJ, Holman KJ, de Paepe A, Francke U, Grau U, Hayward C, Klein HG, Liu W, Nuytink L, Peltonen L, Alvarez Perez AB, Rantamaki T, Junien C, Boileau C. 1998. Marfan Database (third edition): new mutations and new routines for the software. *Nucleic Acids Res* 26:229–233.
- Collod-Beroud G, Le Bourdelles S, Ades L, Ala-Kokko L, Booms P, Boxer M, Child A, Comeglio P, De Paepe A, Hyland JC, Holman K, Kaitila I, Loeys B, Matyas G, Nuytink L, Peltonen L, Rantamaki T, Robinson P, Steinmann B, Junien C, Beroud C, Boileau C. 2003. Update of the UMD-FBN1 mutation database and creation of an FBN1 polymorphism database. *Hum Mutat* 22:199–208.
- Corson GM, Chalberg SC, Dietz HC, Charbonneau NL, Sakai LS. 1993. Fibrillin binds calcium and is coded by cDNAs that reveal a multidomain structure and alternatively spliced exons at the 5' end. *Genomics* 17:476–484.
- Currarino G, Friedman J. 1986. A severe form of congenital contractural arachnodactyly in two newborn infants. *Am J Med Genet* 25:763–773.
- Dietz H, Pyeritz R. 1995. Mutations in the human gene for fibrillin-1 (FBN1) in the Marfan syndrome and related disorders. *Hum Mol Genet* 4(Spec No):1799–1809.
- Downing A, Knott V, Werner J, Cardy C, Campbell I, Handford P. 1996. Solution structure of a pair of calcium-binding epidermal growth factor-like domains: implications for the Marfan syndrome and other genetic disorders. *Cell* 85:597–605.
- Epstein CJ, Graham CB, Hodgkin WE, Hecht F, Motulsky AG. 1968. Hereditary dysplasia of bone with kyphoscoliosis, contractures, and abnormally shaped ears. *J Pediatr* 73:379–386.
- Faivre L, Gorlin RJ, Wirtz MK, Godfrey M, Dagonneau N, Samples JR, Le Merrer M, Collod-Beroud G, Boileau C, Munnich A, Cormier-Daire V. 2003. In frame fibrillin-1 gene deletion in autosomal dominant Weill-Marchesani syndrome. *J Med Genet* 40:34–36.
- Faivre L, Collod-Beroud G, Loeys BL, Child A, Binquet C, Gautier E, Callewaert B, Arbustini E, Mayer K, Arslan-Kirchner M, Kiotsekoglou A, Comeglio P, Marziliano N, Dietz HC, Halliday D, Beroud C, Bonithon-Kopp C, Claustres M, Muti C, Plauchu H, Robinson PN, Ades LC, Biggin A, Benetts B, Brett M, Holman KJ, De Backer J, Coucke P, Francke U, De Paepe A, Jondeau G, Boileau C. 2007. Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study. *Am J Hum Genet* 81:454–466.
- Gallou C, Joly D, Méjean A, Staroz F, Martin N, Tarlet G, Orfanelli M, Bouvier R, Droz D, Chrétien Y, Maréchal J, Richard S, Junien C, Béroud C. 1999. Mutations of the VHL gene is sporadic renal cell carcinoma definition of a risk factor for VHL patients to develop an RCC. *Hum Mutat* 13:464–475.
- Giltay R, Timpl R, Kostka G. 1999. Sequence, recombinant expression and tissue localization of two novel extracellular matrix proteins, fibulin-3 and fibulin-4. *Matrix Biol* 18:469–480.
- Glanville R, Qian R, McClure D, Maslen C. 1994. Calcium binding, hydroxylation, and glycosylation of the precursor epidermal growth factor-like domains of fibrillin-1, the Marfan gene protein. *J Biol Chem* 269:26630–26634.
- Godfrey M, Raghunath M, Cisler J, Bevins CL, DePaepe A, Di Rocco M, Gregoritch J, Imaizumi K, Kaplan P, Kuroki Y, Silberbach M, Superti-Furga A, Van Thienen M-N, Vetter U, Steinmann B. 1995. Abnormal morphology of fibrillin microfibrils in fibroblast cultures from patients with neonatal Marfan syndrome. *Am J Pathol* 146:1414–1421.
- Grenier B, Laugier J, Soutoul J, Desbuquois G. 1969. [Marfan's disease and arthrogryposis. Apropos of a case in a newborn infant]. *Ann Pediatr (Paris)* 16:182–186.
- Gupta PA, Putnam EA, Carmical SG, Kaitila I, Steinmann B, Child A, Danesino C, Metcalfe K, Berry SA, Chen E, Delorme CV, Thong MK, Ades LC, Milewicz DM. 2002. Ten novel FBN2 mutations in congenital contractural arachnodactyly: delineation of the molecular pathogenesis and clinical phenotype. *Hum Mutat* 19:39–48.
- Gupta PA, Wallis DD, Chin TO, Northrup H, Tran-Fadulu VT, Towbin JA, Milewicz DM. 2004. FBN2 mutation associated with manifestations of Marfan syndrome and congenital contractural arachnodactyly. *J Med Genet* 41:e56.
- Handford PA, Mayhew M, Baron M, Winship PR, Campbell ID, Brownlee GG. 1991. Key residues involved in calcium-binding motifs in EGF-like domains. *Nature* 351:164–167.
- Isogai Z, Ono RN, Ushiro S, Keene DR, Chen Y, Mazzieri R, Charbonneau NL, Reinhardt DP, Rifkin DB, Sakai LY. 2003. Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. *J Biol Chem* 278:2750–2757.
- Jeanpierre C, Béroud C, Niaudet P, Junien C. 1998. Software and database for the analysis of mutations in the human WT gene. *Nucleic Acids Res* 26:271–274.
- Kainulainen K, Karttunen L, Puhakka L, Sakai L, Peltonen L. 1994. Mutations in the fibrillin gene responsible for dominant ectopia lentis and neonatal Marfan syndrome. *Nat Genet* 6:64–69.
- Laurent-Puig P, Béroud C, Soussi T. 1998. APC gene: database of germline and somatic mutations in human tumors and cell lines. *Nucleic Acids Res* 26:269–270.
- Lee B, Godfrey M, Vitale E, Hori H, Mattei M-G, Sarfarazi M, Tsipouras P, Ramirez F, Hollister D. 1991. Linkage of Marfan syndrome and a phenotypically related disorder to two different fibrillin genes. *Nature* 352:330–334.
- Lipson E, Viseskul C, Herrmann J. 1974. The clinical spectrum of congenital contractural arachnodactyly. A case with congenital heart disease. *Z Kinderheilkd* 118:1–8.
- Lonnqvist L, Child A, Kainulainen K, Davidson R, Puhakka L, Peltonen L. 1994. A novel mutation of the fibrillin gene causing Ectopia Lentis. *Genomics* 19:573–576.
- Lonnqvist L, Karttunen L, Rantamaki T, Kiely C, Raghunath M, Peltonen L. 1996. A point mutation creating an extra N-glycosylation site in fibrillin-1 results in neonatal Marfan syndrome. *Genomics* 36:468–475.
- Macnab A, D'Orsogna L, Cole D, Baguley P, Adderley R, Patterson M. 1991. Cardiac anomalies complicating congenital contractural arachnodactyly. *Arch Dis Child* 66(10 Spec No):1143–1146.
- Mantel N, Haenszel W. 1959. Statistical aspects of the analysis of data from retrospective studies of disease. *J Natl Cancer Inst* 22:719–748.
- Marfan M. 1896. Un cas de déformation congénitale des quatre membres, plus prononcé aux extrémités, caractérisée par l'allongement des os avec un certain degré d'amincissement. *Société médicale des Hôpitaux* 220–226.

- Mariencheck MC, Davis EC, Zhang H, Ramirez F, Rosenbloom J, Gibson MA, Parks WC, Mecham RP. 1995. Fibrillin-1 and fibrillin-2 show temporal and tissue-specific regulation of expression in developing elastic tissues. *Connect Tissue Res* 31:87–97.
- Maslen C, Babcock D, Raghunath M, Steinmann B. 1997. A rare branch-point mutation is associated with missplicing of fibrillin-2 in a large family with congenital contractural arachnodactyly. *Am J Hum Genet* 60:1389–1398.
- Milewicz DM, Grossfield J, Cao S-N, Kilty C, Covitz W, Jewett T. 1995. A mutation in FBN1 disrupts profibrillin processing and results in isolated skeletal features of the Marfan syndrome. *J Clin Invest* 95:2373–2378.
- Milewicz DM, Michael K, Fisher N, Coselli JS, Markello T, Biddinger A. 1996. Fibrillin-1 (FBN1) mutations in patients with thoracic aortic aneurysms. *Circulation* 94:2708–2711.
- Nagase T, Kikuno R, Ohara O. 2001. Prediction of the coding sequences of unidentified human genes. XXI: The complete sequences of 60 new cDNA clones from brain which code for large proteins. *DNA Res* 8:179–187.
- Nishimura A, Sakai H, Ikegawa S, Kitoh H, Haga N, Ishikiriyama S, Nagai T, Takada F, Ohata T, Tanaka F, Kamasaki H, Saitsu H, Mizuguchi T, Matsumoto N. 2007. FBN2, FBN1, TGFBR1, and TGFBR2 analyses in congenital contractural arachnodactyly. *Am J Med Genet A* 1;143:694–143:698.
- Olofsson A, Ichijo H, Moren A, ten Dijke P, Miyazono K, Heldin CH. 1995. Efficient association of an amino-terminally extended form of human latent transforming growth factor-beta binding protein with the extracellular matrix. *J Biol Chem* 270:31294–31297.
- Park ES, Putnam EA, Chitayat D, Child A, Milewicz DM. 1998. Clustering of FBN2 mutations in patients with congenital contractural arachnodactyly indicates an important role of the domains encoded by exons 24 through 34 during human development. *Am J Med Genet* 78:350–355.
- Pereira L, D'Alessio M, Ramirez F, Lynch JR, Sykes B, Pangilinan T, Bonadio J. 1993. Genomic organization of the sequence coding for fibrillin, the defective gene product in Marfan Syndrome. *Hum Mol Genet* 2:961–968.
- Putnam EA, Zhang H, Ramirez F, Milewicz DM. 1995. Fibrillin-2 (FBN2) mutations result in the Marfan-like disorder, congenital contractural arachnodactyly. *Nat Genet* 11:456–458.
- Putnam E, Park E, Aalfs C, Hennekam R, Milewicz D. 1997. Parental somatic and germ-line mosaicism for a FBN2 mutation and analysis of FBN2 transcript levels in dermal fibroblasts. *Am J Hum Genet* 60:818–827.
- Quondamatteo F, Reinhardt DP, Charbonneau NL, Pophal G, Sakai LY, Herken R. 2002. Fibrillin-1 and fibrillin-2 in human embryonic and early fetal development. *Matrix Biol* 21:637–646.
- Raghunath M, Superti-Furga A, Godfrey M, Steinmann B. 1993. Decreased extracellular deposition of fibrillin and decorin in neonatal Marfan syndrome fibroblasts. *Hum Genet* 90:511–515.
- Ramirez F, Pereira L. 1999. The fibrillins. *Int J Biochem Cell Biol* 31:255–259.
- Rao Z, Handford P, Mayhew M, Knott V, Brownlee GG, Stuart D. 1995. The structure of a Ca(2+)-binding epidermal growth factor-like domain: its role in protein-protein interactions. *Cell* 82:131–141.
- Rees DJ, Jones IM, Handford PA, Walter SJ, Esnouf MP, Smith KJ, Brownlee GG. 1988. The role of beta-hydroxyaspartate and adjacent carboxylate residues in the first EGF domain of human factor IX. *EMBO J* 7:2053–2061.
- Ritty TM, Broekelmann TJ, Werneck CC, Mecham RP. 2003. Fibrillin-1 and -2 contain heparin-binding sites important for matrix deposition and that support cell attachment. *Biochem J* 375(Pt 2):425–432.
- Soussi T, Dehouche K, Bérout C. 2000. p53 Website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. *Hum Mutat* 15:105–113.
- Superti-Furga A, Raghunath M, Willems PJ. 1992. Deficiencies of fibrillin and decorin in fibroblast cultures of a patient with neonatal Marfan syndrome. *J Med Genet* 29:875–878.
- Tsipouras P, Del Mastro R, Sarfarazi M, Lee B, Vitale E, Child A, Godfrey M, Devereux RB, Hewett D, Steinmann B, Viljoen D, Sykes BC, Kilpatrick M, Ramirez F, The International Marfan Syndrome Collaborative Study. 1992. Genetic linkage of the Marfan syndrome, ectopia lentis, and congenital contractural arachnodactyly to the fibrillin genes on chromosomes 15 and 5. *N Engl J Med* 326:905–909.
- Varret M, Rabes JP, Collod-Beroud G, Junien C, Boileau C, Beroud C. 1997. Software and database for the analysis of mutations in the human LDL receptor gene. *Nucleic Acids Res* 25:172–180.
- Varret M, Rabes J, Thiart R, Kotze M, Baron H, Cenarro A, Descamps O, Ehardt M, Hondelijn J, Kostner G, Miyake Y, Pocovi M, Schmidt H, Schuster H, Stuhmann M, Yamamura T, Junien C, Bérout C, Boileau C. 1998. LDLR Database, 2nd edition. New additions to the database and the software, and results of the first molecular analysis. *Nucleic Acids Res* 26:248–252.
- Villegier L, Abifadel M, Allard D, Rabes J, Thiart R, Kotze M, Bérout C, Junien C, Boileau C, Varret M. 2002. The UMD-LDLR database: additions to the software and 490 new entries to the database. *Hum Mutat* 20:81–87.
- Wang M, Price CE, Han J, Cislis J, Imaizumi K, van Thienen M-N, DePaepe A, Godfrey M. 1995a. Recurrent mis-splicing of fibrillin exon 32 in two patients with neonatal Marfan syndrome. *Hum Mol Genet* 4:607–613.
- Wang M, Tsipouras P, Godfrey M. 1995b. Fibrillin-2 (FBN2) mutation in congenital contractural arachnodactyly. *Am J Hum Genet* 57:P1339.
- Wang M, Clericuzio CL, Godfrey M. 1996. Familial occurrence of typical and severe lethal congenital contractural arachnodactyly caused by missplicing of exon 34 of fibrillin-2. *Am J Hum Genet* 59:1027–1034.
- Wautot V, Vercherat C, Lespinasse J, Chambe B, Lenoir G, Zhang C, Bérout C, Calender A. 2002. Germline mutation profile of the MEN1 gene in multiple endocrine neoplasia type 1 and correlations between phenotype and the functional domains of MEN1 protein. *Hum Mutat* 20:35–47.
- Yang Q, Ota K, Tian Y, Kumar A, Wada J, Kashihara N, Wallner E, Kanwar YS. 1999. Cloning of rat fibrillin-2 cDNA and its role in branching morphogenesis of embryonic lung. *Dev Biol* 212:229–242.
- Yuan X, Downing AK, Knott V, Handford PA. 1997. Solution structure of the transforming growth factor beta-binding protein-like module, a domain associated with matrix fibrils. *EMBO J* 16:6659–6666.
- Zhang H, Apfelroth S, Hu W, Davis E, Sanguineti C, Bonadio J, Mecham R, Ramirez F. 1994. Structure and expression of fibrillin-2, a novel microfibrillar component preferentially located in elastic matrices. *J Cell Biol* 124:855–863.
- Zhang HY, Chu ML, Pan TC, Sasaki T, Timpl R, Ekblom P. 1995. Extracellular matrix protein fibulin-2 is expressed in the embryonic endocardial cushion tissue and is a prominent component of valves in adult heart. *Dev Biol* 167:18–26.